Characteristics and risk factors of COVID-19 mortality in Tamaulipas, one year after the pandemic
DOI:
https://doi.org/10.29059/cienciauat.v17i1.1652Keywords:
comorbidity, coronavirus, CKD, case fatality rate, TamaulipasAbstract
Coronavirus 19 (COVID-19) is a prevalent and globally disseminated viral disease that has become a pandemic associated with a high case fatality rate. To date, there are no published studies that describe the influence of the variables associated with the disease, specifically in the border state of Tamaulipas, Mexico. The objective of the present study was to assess the characteristics, complications, fatality rates and risk factors associated to mortality in patients positive to COVID-19 in Tamaulipas, one year after the local emergency. Descriptive frequency of characteristics, complications for prevalence and case fatality rates were used. A multivariate logistic regression model was adjusted to estimate the meaningful risk factors, and Kaplan-Meier survival curves were used to describe the most important comorbidities. The analysis indicated higher infection rates in patients of productive age, with a significant death probability in male patients from the age of 40. The risks associated with hospitalization, such as endotracheal intubation and the presence of pneumonia are important risk factors. Comorbidities with high prevalence; diabetes, hypertension, obesity, and chronic kidney disease (CKD) were significantly associated (P < 0.01) with higher COVID-19 mortality risk in the assessed population. The present study demonstrated some COVID-19 general patterns on frequency and mortality rates. It also suggested particularities in factors associated to mortality in the Tamaulipas population, which require proper attention in vulnerable groups, especially in future outbreaks of the disease.
References
Alizadehsani, R., Alizadeh, S. Z., Behjati, M., Roshanzamir, Z., Hussain, S., Abedini, N., …, and Moradnejad, P. (2021). Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients. Journal of Medical Virology. 93(4): 2307-2320.
Bellan, M., Patti, G., Hayden, E., Azzolina, D., Pirisi, M., Acquaviva, A., …, and Avanzi, G. C. (2020). Fatality rate and predictors of mortality in an Italian cohort of hospitalied COVID-19 patients. Scientific Reports. 10(1): 1-10.
Berlin, I., Thomas, D., Le-Faou, A. L., and Cornuz, J. (2020). COVID-19 and smoking. Nicotine and Tobacco Research. 22(9): 1650-1652.
Bertsimas, D., Lukin, G., Mingardi, L., Nohadani, O., Orfanoudaki, A., Stellato, B., …, and Schneider, M. (2020). COVID-19 mortality risk assessment: An international multi-center study. PloS One. 15(12): e0243262.
Chávez-Gómez, N. L., Cabello-López, A., Gopar-Nieto, R., Aguilar-Madrid, G., Marin-López, K. S., Aceves-Valdez, M., … y Juárez-Pérez, C. A. (2017). Enfermedad renal crónica en México y su relación con los metales pesados. Revista Médica del Instituto Mexicano del Seguro Social. 55(6): 725-734.
DOF, Diario Oficial de la Federación (2015). Acuerdo por el que se emite la Política de Transparencia, Gobierno Abierto y Datos Abiertos de la Administración Pública Federal 2021-2024. [En línea]. Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5622579&fecha=30/06/2021. Fecha de consulta: 5 de agosto de 2021.
Emami, A., Javanmardi, F., Pirbonyeh, N., and Akbari, A. (2020). Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archives of Academic Emergency Medicine. 8(1): e35.
Escobedo-de-la-Peña, J., Rascón-Pacheco, R. A., de-Jesús-Ascencio-Montiel, I., González-Figueroa, E., Fernández-Gárate, J. E., Medina-Gómez, O. S., …, and Borja-Aburto, V. H. (2021). Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Archives of Medical Research. 52(4): 443-449.
Gobierno del Estado de Tamaulipas (2020). Comunicado Técnico diario nuevo Cornonavirus en el mundo (COVID-19). [En línea]. Disponible en: https://coronavirus.tamaulipas.gob.mx/wp-content/uploads/sites/104/2020/03/comunicado_tecnico_diario_covid-19_2020.03.17.pdf. Fecha de consulta: 20 de septiembre de 2021.
Henry, B. M. and Lippi, G. (2020). Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International Urology and Nephrology. 52(6): 1193-1194.
Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., …, and Hill, M. (2021). Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clinical Infectious Diseases. 72(9): e206-e214.
Lara-Rivera, A. L., Parra-Bracamonte, N. y López-Villalobos, G. M. (2021). Tasas de letalidad y factores de riesgo por COVID-19 en México. Revista Cubana de Salud Pública. 47(4): e2872.
Li, J., Huang, D. Q., Zou, B., Yang, H., Hui, W. Z., Rui, F., …, and Teng, M. L. P. (2021). Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. Journal of Medical Virology. 93(3): 1449-1458.
Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., ...., and Zhang, C. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology. 146(1): 110-118.
Maksimowski, N., Williams, V. R., and Scholey, J. W. (2020). Kidney ACE2 expression: Implications for chronic kidney disease. PLoS One. 15(10): e0241534.
Navarro, R. B. y Cappello, H. M. (1986). La Identidad y Caracter Nacionales en México—La Frontera de Tamaulipas—. Revista de Psicología Social. 1(2): 153-166.
Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M. H., Sarraf, P., and Djalali, M. (2020). Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. The Aging Male. 23(5): 1416-1424.
Parra-Bracamonte, G. M., Lopez-Villalobos, N., and Parra-Bracamonte, F. E. (2020). Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Annals of Epidemiology. 52: 93-98.
Parra-Bracamonte, G. M., Parra-Bracamonte, F. E., Lopez-Villalobos, N., and Lara-Rivera, A. L. (2021). Chronic kidney disease is a very significant comorbidity for high risk of death in patients with COVID-19 in Mexico. Nephrology. 26(3): 248-251.
Rajpal, A., Rahimi, L., and Ismail-Beigi, F. (2020). Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. Journal of Diabetes. 12(12): 895-908.
Secretaría de Salud (2020). Informe Técnico Diario COVID-19 MÉXICO, en Gobierno de México. [En línea]. Disponible en: https://www.gob.mx/salud/documentos/informe-tecnico-diario-covid19-2022. Fecha de consulta: 20 de septiembre de 2021.
Secretaría General de Gobierno (2019). Periódico Oficial del Estado de Tamaulipas. [En línea]. Disponible en: http://po.tamaulipas.gob.mx/wp-content/uploads/2019/02/cxliv-23-200219F-ANEXO.pdf. Fecha de consulta: 20 de septiembre de 2021.
Torres-Toledano, M., Granados-García, V. y López-Ocañac, L. R. (2017). Carga de la enfermedad renal crónica en México. Revista Médica del Instituto Mexicano del Seguro Social. 55(2): 118-123.
Vardavas, C. I. and Nikitara, K. (2020). COVID-19 and smoking: A systematic review of the evidence. Tobacco Induced Diseases. 18(20): 1-4.
Weiss, P. and Murdoch, D. R. (2020). Clinical course and mortality risk of severe COVID-19. The Lancet. 395(10229): 1014-1015.
WHO, World Health Organization (2022a). WHO Coronavirus (COVID-19) Dashboard. [En línea]. Disponible en: https://covid19.who.int/. Fecha de consulta: 19 de enero de 2022.
WHO, World Health Organization (2022b). Coronavirus disease (COVID-19) Mexico situation report. [En línea]. Disponible en: https://covid19.who.int/region/amro/country/mx. Fecha de consulta: 19 de enero de 2022.
Yu, C., Lei, Q., Li, W., Wang, X., Liu, W., Fan, X., and Li, W. (2020). Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. American Journal of Preventive Medicine. 59(2): 168-175.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Universidad Autónoma de Tamaulipas
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
